KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $269.7 million.

  • Charles River Laboratories International's Accumulated Expenses rose 2777.19% to $269.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $269.7 million, marking a year-over-year increase of 2777.19%. This contributed to the annual value of $232.0 million for FY2024, which is 183.69% up from last year.
  • Latest data reveals that Charles River Laboratories International reported Accumulated Expenses of $269.7 million as of Q3 2025, which was up 2777.19% from $231.6 million recorded in Q2 2025.
  • Over the past 5 years, Charles River Laboratories International's Accumulated Expenses peaked at $269.7 million during Q3 2025, and registered a low of $190.9 million during Q1 2024.
  • For the 5-year period, Charles River Laboratories International's Accumulated Expenses averaged around $222.8 million, with its median value being $224.2 million (2023).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 4241.43% in 2021, then tumbled by 1814.82% in 2022.
  • Charles River Laboratories International's Accumulated Expenses (Quarter) stood at $246.1 million in 2021, then fell by 10.71% to $219.8 million in 2022, then rose by 3.67% to $227.8 million in 2023, then increased by 1.84% to $232.0 million in 2024, then increased by 16.24% to $269.7 million in 2025.
  • Its last three reported values are $269.7 million in Q3 2025, $231.6 million for Q2 2025, and $242.5 million during Q1 2025.